Tirzepatide

Clinical maturity: Approved, large completed Phase 3 programme

Approved products (Mounjaro, Zepbound) are once-weekly subcutaneous injections. No approved oral or other-route formulation exists.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

A single molecule that activates two incretin receptors at once — GIP and GLP-1 — designed to improve metabolic outcomes beyond GLP-1 alone.

• Greater average weight loss than single-agonist GLP-1s
• Strong glycaemic control
• Improves obstructive sleep apnoea severity in people with obesity

Randomised trials, including head-to-head comparisons in some settings, show large average weight reduction and strong glycaemic effects. Real differences between individuals are wide — trial averages are not personal forecasts.

• Large randomised Phase 3 trials in type 2 diabetes and obesity.
• Comparative trials against a single GLP-1 agonist in defined populations.
• Trials in obesity-related conditions such as sleep apnoea.

• Receptor pharmacology characterising biased signalling at GIP and GLP-1 receptors.
• Rodent metabolic models of combined incretin agonism.

Animal and cell findings are Level 1–2 evidence.

• GLP-1 receptor agonism: insulin secretion, appetite suppression, slowed gastric emptying.
• GIP receptor agonism: additional effects on adipose tissue handling and possibly nausea tolerance.

• Very common: gastrointestinal effects, strongly dose-related.
• Notable: gallbladder events, pancreatitis (uncommon), dehydration.
• Same precautionary thyroid labelling class as other incretin agonists in some regions.

Approved in multiple regions for type 2 diabetes (Mounjaro) and, under a separate brand (Zepbound), for chronic weight management. In December 2024 the FDA approved Zepbound as the first medication for obstructive sleep apnoea in adults with obesity. Additional indications vary by regulator.

• 2024-12-20 · United States

  FDA approved Zepbound as the first medication for obstructive sleep apnoea in adults with obesity.

• L5Practice-changingPhase 3 obesity programme

  Randomised, double-blind, placebo-controlled — Adults with obesity

  Large average weight reduction; wide individual variation within trial arms.

• Long-term cardiovascular and mortality outcome data reaching maturity.
• Robust comparative effectiveness data against triple agonists.

• Regulatory / labelFDA press release — First medication approved for obstructive sleep apnoea (Zepbound, 20 December 2024)

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

No recorded changes yet. Baseline position set on 2026-08-23.